RhumbLine Advisers’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-719
| Closed | -$14.7K | – | 4215 |
|
|
2024
Q2 | $14.7K | Sell |
719
-1,136
| -61% | -$23.3K | ﹤0.01% | 3915 |
|
|
2024
Q1 | $83.7K | Buy |
1,855
+43
| +2% | +$1.94K | ﹤0.01% | 3492 |
|
|
2023
Q4 | $85.5K | Buy |
1,812
+100
| +6% | +$4.72K | ﹤0.01% | 3499 |
|
|
2023
Q3 | $69.3K | Sell |
1,712
-54
| -3% | -$2.19K | ﹤0.01% | 3572 |
|
|
2023
Q2 | $188K | Sell |
1,766
-327
| -16% | -$34.8K | ﹤0.01% | 3265 |
|
|
2023
Q1 | $625K | Buy |
2,093
+165
| +9% | +$49.3K | ﹤0.01% | 2339 |
|
|
2022
Q4 | $663K | Buy |
1,928
+31
| +2% | +$10.7K | ﹤0.01% | 2338 |
|
|
2022
Q3 | $359K | Buy |
1,897
+115
| +6% | +$21.8K | ﹤0.01% | 2645 |
|
|
2022
Q2 | $376K | Buy |
1,782
+644
| +57% | +$136K | ﹤0.01% | 2633 |
|
|
2022
Q1 | $381K | Buy |
1,138
+132
| +13% | +$44.2K | ﹤0.01% | 2541 |
|
|
2021
Q4 | $327K | Buy |
1,006
+49
| +5% | +$15.9K | ﹤0.01% | 2679 |
|
|
2021
Q3 | $465K | Buy |
957
+51
| +6% | +$24.8K | ﹤0.01% | 2580 |
|
|
2021
Q2 | $421K | Buy |
906
+58
| +7% | +$27K | ﹤0.01% | 2642 |
|
|
2021
Q1 | $586K | Sell |
848
-104
| -11% | -$71.9K | ﹤0.01% | 2412 |
|
|
2020
Q4 | $704K | Buy |
952
+88
| +10% | +$65.1K | ﹤0.01% | 2290 |
|
|
2020
Q3 | $599K | Sell |
864
-102
| -11% | -$70.7K | ﹤0.01% | 2201 |
|
|
2020
Q2 | $820K | Buy |
+966
| New | +$820K | ﹤0.01% | 2126 |
|